Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
3/30/26 Gan & Lee Pharmaceuticals GZR-4 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
3/30/26 Bristol Myers Squibb (BMY) Camzyos for Cardiomyopathy - Hypertrophic Subscribers Only Subscribers Only Subscribers Only
3/29/26 Diamyd (DMYDB) Diamyd for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only
3/29/26 Merck & Co. (MRK) Winrevair for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Subscribers Only Subscribers Only Subscribers Only
3/28/26 Takeda (4502) zasocitinib for Psoriasis Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results